Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) α-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop.

The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop.

The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.

Described here are methods, compositions, and systems for generating transgenic islet cells suitable for xenotransplantation.

Described here are methods, compositions, and systems for generating transgenic islet cells suitable for xenotransplantation.

To provide a topical formulation that contains rapamycin, has excellent stability, and is effective in treating a skin disease.

A topical formulation including (a) rapamycin, (b) at least one selected from the group consisting of ethylene glycol salicylate, diethyl sebacate, and triacetin, and (c) propylene glycol and/or polyethylene glycol, the topical formulation further including an antioxidant, and the topical formulation further including a solution of an antioxidant in a lipophilic solvent are provided.

To provide a topical formulation that contains rapamycin, has excellent stability, and is effective in treating a skin disease.

A topical formulation including (a) rapamycin, (b) at least one selected from the group consisting of ethylene glycol salicylate, diethyl sebacate, and triacetin, and (c) propylene glycol and/or polyethylene glycol, the topical formulation further including an antioxidant, and the topical formulation further including a solution of an antioxidant in a lipophilic solvent are provided.

The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.

The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.

The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.